The Society for Immunotherapy of Cancer (SITC) Nonmelanoma Skin Cancer Immunotherapy Guideline Expert Panel is pleased to invite public comment from January 11–27, 2022 for the draft of the forthcoming manuscript, "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer."The SITC Nonmelanoma Skin Cancer Immunotherapy Guideline Expert Panel developed this CPG to provide practical guidance to clinicians on the optimal use of immunotherapy for nonmelanoma skin cancer (including cutaneous squamous cell carcinoma, Merkel cell carcinoma, basal cell carcinoma, and other) amidst the current therapeutic landscape. This CPG provides recommendations for the use of currently approved immunotherapies including pembrolizumab, cemiplimab, and avelumab. Additionally, this CPG also covers discussions concerning staging and biomarkers, patient selection, toxicity management and clinical endpoints, and patient quality of life issues.SITC’s public open comment period allows for key stakeholders and other experts in the field – both within and outside of our membership – to provide comment on the confidential manuscript draft prior to publication. SITC is committed to maintaining full transparency in our guideline development process, in alignment with the Institute of Medicine’s standards, for the ultimate purpose of developing quality clinical practice guidelines to aid practitioners in providing the best possible care to their patients.Instructions for participating in the open comment period are provided below. All participants must complete and sign a non-disclosure and confidentiality agreement prior to obtaining the draft manuscript. All comments must be received by January 27, 2022 to be considered.
Instructions for Requesting Draft Manuscript
Download the non-disclosure and confidentiality agreement HERE
Email the completed document to firstname.lastname@example.org
A copy of the guideline will be sent within 1-2 business days after receipt of the complete form (anonymous comments will not be accepted)
Further instructions about how to provide comment will be included with the draft
All comments received during the open comment period will be reviewed by the Nonmelanoma Skin Cancer Immunotherapy Guideline Expert Panel leadership. Comments are advisory only and SITC is not obligated to make any suggested changes based on comments received. SITC will consider all submissions, but will not respond directly to individual commenters.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com